Johnson & Johnson enters collaborations with two Canadian biotechs

14 October 2015

Janssen Biotech, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), today announced collaborations with two Canadian biotechnology companies, Toronto-based Novera Therapeutics and Montreal-based enGene.

The agreements, facilitated by Johnson & Johnson Innovation, seek to advance novel therapeutics for the treatment of hematological malignancies and inflammatory bowel disease (IBD).

These agreements follow the recent announcement that Johnson & Johnson Innovation, JLABS will be locating its first ex-US incubator in Toronto. JLABS @ Toronto will open in Spring 2016 and support regional entrepreneurs and start-up companies with lab space, programs, and potential investment partners as they work to build successful early-stage companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK